Kelun-Biotech Reports Phase II Data, Plans Global Phase III Study

Kelun-Biotech reported Phase II results for sacituzumab tirumotecan plus pembrolizumab in first-line cisplatin-ineligible locally advanced or metastatic urothelial cancer, citing antitumor activity and manageable safety. The company said the data support starting the global Phase III TroFuse-055 study.